Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Healios KK ( (JP:4593) ).
Healios K.K. has been selected for a JPY 7 billion subsidy under Japan’s METI program to support capital investment in regenerative, cell, and gene therapy manufacturing facilities. This funding will enable Healios to expand its CDMO business, enhancing its competitive edge in the global market by integrating advanced technologies and establishing a robust international platform. The initiative aligns with Japan’s industrial policy and aims to strengthen Healios’s position as a leader in regenerative medicine, fostering new partnerships and enhancing shareholder value.
The most recent analyst rating on (JP:4593) stock is a Buy with a Yen320.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
More about Healios KK
HEALIOS K.K. is a leading clinical stage biotechnology company in Japan, focusing on regenerative medicine through the use of stem cells. The company is pioneering the development of regenerative therapies, particularly utilizing somatic stem cells and iPS cells, to offer new treatments for diseases with limited options.
Average Trading Volume: 7,509,724
Technical Sentiment Signal: Hold
Current Market Cap: Yen54.12B
Find detailed analytics on 4593 stock on TipRanks’ Stock Analysis page.